SOPHiA GENETICS

SOPHiA GENETICS ROCE

The Return on Capital Employed (ROCE) of SOPHiA GENETICS (SOPH) as of Nov 9, 2026 is -160.79 %. In the previous year, Return on Capital Employed (ROCE) was -68.99 % — a change of 133.07% (lower).

ROCE

-160.79 %

YoY

133.07%

Last updated:

In 2025, SOPHiA GENETICS's return on capital employed (ROCE) was -160.79 %, a 133.07% increase from the -68.99 % ROCE in the previous year.

The SOPHiA GENETICS ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2019
-147.12 USD
Jan 1, 2020
-40.18 USD
Jan 1, 2021
-26.46 USD
Jan 1, 2022
-43.88 USD
Jan 1, 2023
-49.41 USD
Jan 1, 2024
-68.99 USD
Jan 1, 2025
-160.79 USD
The SOPHiA GENETICS ROCE history
YEARROCEYoY
-160.79 %+133.07%
-68.99 %+39.63%
-49.41 %+12.59%
-43.88 %+65.85%
-26.46 %-34.15%
-40.18 %-72.69%
-147.12 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SOPHiA GENETICS Stock analysis

What does SOPHiA GENETICS do? Sophia Genetics SA is a Swiss company that was founded in 2011. The idea behind it was to improve genome sequencing and data analysis in order to make faster and more precise medical diagnoses. Sophia Genetics has since become a leading provider of artificial intelligence and data analysis in the medical field. The business model of Sophia Genetics is based on providing doctors and medical facilities with corresponding data analysis tools and platforms. Sophia Genetics' algorithms help to identify genetic anomalies and develop personalized therapies. This personalized medicine aims to improve healthcare. Sophia Genetics is divided into various sectors. The core sectors include oncology, pediatrics, cardiology, and neurology. In these specialized fields, Sophia Genetics' platforms and tools are used to optimize genome sequencing and data analysis, thus enabling faster and more precise diagnoses. The company offers a variety of products that help doctors and medical facilities create successful diagnoses and therapies. Sophia Genetics' flagship product is the Sophia Artificial Intelligence (AI) platform. This platform is used by doctors, clinics, and research institutions to analyze complex data and identify the genetic causes of diseases. The Sophia AI platform provides fast, precise, and secure genome sequencing and data analysis. Sophia Genetics also offers the Sophia DDM system. The DDM system is a cloud-based data exchange system that provides doctors and medical facilities with a secure way to exchange confidential medical data. The system also allows for the collection and analysis of information about diseases and disease progression in the population, in order to enable better healthcare. Another important product of Sophia Genetics is the Sophia Hereditary Cancer Solution. This product helps in the early detection of hereditary cancer. The Sophia Hereditary Cancer Solution provides fast and precise genetic diagnostics to identify family members at increased risk of cancer and take appropriate measures. Another product of Sophia Genetics is Sophia Radiomics. This software uses artificial intelligence and machine learning to detect and characterize diseases based on X-ray and CT scans. By analyzing large amounts of data, the Sophia Radiomics software can assist doctors in making more precise diagnoses and better treatment decisions. Sophia Genetics relies on close collaboration with medical facilities and research institutions worldwide. The company now has customers in over 60 countries and is a partner to more than 1,000 hospitals worldwide. Sophia Genetics' platforms and tools have already helped many people to be diagnosed and treated faster and more accurately. Overall, Sophia Genetics is an innovative company that has revolutionized medical diagnostics. With its advanced platforms and tools, the company provides doctors and medical facilities with an excellent opportunity to develop personalized therapies and enable better healthcare. SOPHiA GENETICS is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling SOPHiA GENETICS's Return on Capital Employed (ROCE)

SOPHiA GENETICS's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing SOPHiA GENETICS's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

SOPHiA GENETICS's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in SOPHiA GENETICS’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about SOPHiA GENETICS stock

Return on Capital Employed (ROCE) of SOPHiA GENETICS is -160.79 % in 2025.

Return on Capital Employed (ROCE) of SOPHiA GENETICS changed from -68.99 % to -160.79 %, representing a 133.07% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) SOPHiA GENETICS since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s SOPHiA GENETICS with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — SOPHiA GENETICS

All Key Metrics — SOPHiA GENETICS